Table 1.
Antimicrobial susceptibility testing results of 83 isolates of K. pneumoniae collected from Mofid Children and Taleghani Hospitals, Tehran, Iran.
| Antibiotic | Resistant number (%) | Intermediate number (%) | Sensitive number (%) |
|---|---|---|---|
| Aztreonam (10 μg) | 49 (59%) | 3 (3.6%) | 31 (37.3%) |
| Meropenem (10 μg) | 20 (24%) | 2 (2.4%) | 61 (73.5%) |
| Gentamicin (10 μg) | 29 (35%) | 3 (3.6%) | 51 (61.5%) |
| Ciprofloxacin (30 μg) | 46 (55.5%) | 4 (4.8%) | 33 (39.7%) |
| Amikacin (30 μg) | 12 (14.4%) | 4 (4.8%) | 67 (80.7%) |
| Ceftazidime (30 μg) | 46 (55.4%) | 3 (3.6%) | 34 (41%) |
| Imipenem (10 μg) | 20 (24%) | 2 (2.4%) | 61 (73.5%) |
| Cefotaxime (30 μg) | 50 (60.2%) | 2 (2.4%) | 31 (37.3%) |
| Cefepime (FEP, 30 μg) | 30 (36.15%) | 9 (10.8%) | 44 (53.05%) |
| Tetracycline (TE, 10 μg) | 33 (39.7%) | 3 (3.6%) | 57 (68.6%) |
| Ampicillin (AMP, 10 μg) | 65 (78.3%) | 2 (2.4%) | 16 (19.2%) |
| Piperacillin (PIP, 100 μg) | 50 (60.2%) | 0 (0.0%) | 33 (39.7%) |
| Ceftriaxone (CRO, 30 μg) | 49 (59%) | 2 (2.4%) | 32 (38.5%) |
| Cefpodoxime (CPD, 30 μg) | 57 (68.6%) | 3 (3.6%) | 23 (27.7%) |
| Tigecycline (TGC, 15 μg) | 5 (6.02%) | 25 (30.1%) | 53 (63.8%) |
| Doripenem (DOR, 10 μg) | 20 (24%) | 1 (1.2%) | 62 (74.6%) |
| Ertapenem (ETP, 10 μg) | 21 (25.3%) | 2 (2.4%) | 57 (68.6%) |
| Piperacillin/tazobactam (PTZ, 100/10 μg) | 22 (26.5%) | 5 (6.02%) | 56 (67.4%) |
| Fosfomycin/trometamol (FOT, 200 μg) | 3 (3.6%) | 12 (14.4%) | 68 (82%) |